Baird Medical Investment opened lower at $0.10, compared with its previous close of $0.10. In the last trading session, the stock traded between $0.09 and $0.11. It showed an upward intraday trend.
An investment of $100 made 3 years ago in Baird Medical Investment is now worth
$ 1.78
Resulting in a loss of
$ 98.22 (98.22%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
+$0.00 (+2.88%)
Day High
$0.11
Day Low
$0.09
Day Open
$0.10
Prev Close
$0.10
Volume
9,98,08,035
1W Return
-0.93%
1M Return
-85.64%
3M Return
-91.08%
6M Return
-93.63%
1Y Return
-91.37%
Market Cap ($ Mn)
3
PE Ratio
-
PB Ratio
1.10
PEG Ratio
-
ROE
-77.50%
ROCE
-62.94%
EPS (TTM)
-
1 Week
-0.93%
1 Month
-85.64%
3 Months
-91.08%
6 Months
-93.63%
9 Months
-87.25%
No data available.
Baird Medical enters South Korea market through ALLIS MED partnership
Baird Medical signs distribution agreement with ALLIS MED for South Korea. ALLIS MED to manage regulatory submissions with Ministry of Food and Drug Safety. Partnership introduces microwave ablation technology to Korean market. Company entered Argentina, Egypt, Pakistan, and Vietnam in 2026.
TodayBaird Medical stock falls 33% after hours despite FDA filing
Baird Medical shares fell 33% in after-hours trading Thursday. Partner Alpmed submitted FDA 510(k) and EU CE applications for IRE system. Targeting FDA clearance and CE marking in 2027. Stock closed regular session up 47.47% at $0.16 before dropping. Market capitalization stands at approximately $5 million.
7 days agoBaird Medical secures medical device registrations in Vietnam and Egypt
Secured Class C medical device registrations in Vietnam for J-series, G-series, and MTI-5AT/ET products. Received preliminary approval from Egyptian Drug Authority for BD-GT Microwave Ablation System. Expands addressable patient population in Southeast Asia and Middle East markets. Builds on FDA 510(k) clearance obtained in November 2023 for US market entry.
24 days agoBaird Medical secures Pakistan regulatory approvals for ablation devices
Baird Medical Investment Holdings Ltd. secured product registrations from the Drug Regulatory Authority of Pakistan for its BD-GT Microwave Ablation System and T-1610 Disposable Microwave Ablation Needle. This development expands on the company's January 2026 commercial launch at the Armed Forces Institute of Radiology & Imaging, strengthening its regulatory and commercial foundation in the Pakistani market.
2mo agoBaird Medical, Alpmed Sign Deal To Globalize Next-Gen IRE Tech
Baird Medical and Tianjin Yuanshan (Alpmed) signed a strategic deal on Aug. 10, 2026, to globalize IRE technology. They target an FDA 510(k) submission by end-2026 and clearance in 2027 for a tumor ablation device. Baird Medical holds worldwide commercial rights.
3mo agoBaird Medical completes first procedures in Vietnam and Argentina
Baird Medical Investment Holdings Ltd. announced on June 29, 2026, the successful completion of the first procedures using its Microwave Ablation (MWA) technology in Vietnam and Argentina. This expansion into two new markets highlights the growing global adoption of its minimally invasive MWA solutions.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $109.29 | -1.06% | $1,89,283.94M | 36.28 | |
| $449.53 | -0.11% | $1,55,826.88M | 42.73 | |
| $101.61 | +0.02% | $1,29,976.46M | 24.46 | |
| $318.79 | -1.70% | $1,21,360.48M | 34.27 | |
| $45.13 | +0.96% | $65,414.72M | 18.96 | |
| $105.81 | +1.73% | $60,840.75M | 53.70 | |
| $214.52 | +0.90% | $58,432.46M | 44.07 | |
| $82.60 | -1.26% | $37,346.60M | 16.49 | |
| $42.16 | +3.06% | $37,044.18M | 89.05 | |
| $72.46 | -2.16% | $35,027.16M | 54.55 | |
| $237.20 | +1.61% | $33,458.08M | 23.04 | |
| $80.35 | +0.53% | $29,964.75M | 36.04 |
An investment of $100 made 3 years ago in Baird Medical Investment is now worth
$ 1.78
Resulting in a loss of
$ 98.22 (98.22%)
Note: Past profits do not guarantee future returns.
